Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units on February 21, 2026. These units, granted on November 8, 2024, convert into common stock at no cost as part of a four-year equity award vesting schedule.
Guardant Health, Inc. files its annual report describing a precision oncology business built around blood and tissue tests, real‑world data and AI analytics to manage cancer across screening, therapy selection and recurrence monitoring. Key products include Guardant360 liquid and tissue tests, Guardant Reveal for minimal residual disease and therapy response, and the Shield blood test for colorectal cancer screening.
The company highlights FDA approvals for Guardant360 CDx and Shield, Medicare coverage for several assays, and expanding global partnerships in Europe and Asia to run its technology locally. Its Smart Platform integrates genomic and epigenomic data to power multiple tests and biopharma offerings. As of the most recent reference dates, non‑affiliate equity market value was about $6.2 billion and common shares outstanding were 131,170,441.
Guardant Health, Inc. reported strong growth for the fourth quarter and full year 2025 while still operating at a sizeable loss. Fourth quarter revenue rose 39% to $281.3 million, with Oncology revenue up 30% to $189.9 million and Screening revenue reaching $35.1 million on about 38,000 Shield tests. Non-GAAP gross margin improved to 66%.
For 2025 as a whole, revenue grew 33% to $982.0 million, driven by Oncology revenue of $683.6 million and Screening revenue of $79.7 million on roughly 87,000 Shield tests. Non-GAAP gross margin increased to 66%, but the company recorded a GAAP net loss of $416.3 million, or $3.32 per share, and a non-GAAP net loss of $228.1 million.
Free cash flow burn improved to $233.1 million from $274.9 million. For 2026, Guardant Health expects revenue between $1.25 billion and $1.28 billion, representing growth of 27% to 30%, with continued expansion in Oncology, Biopharma & Data, and a sharp increase in Screening revenue and test volumes.
Guardant Health director Manuel Hidalgo Medina reported acquiring shares through equity awards. On the vesting of a restricted stock unit grant on July 17, 2024, 232 restricted stock units converted into 232 shares of common stock at a price of $0.00 per share, reflecting an exercise or conversion of a derivative security rather than an open-market purchase. After these transactions, he directly holds 6,729 restricted stock units and 1,493 shares of common stock. The award vests over four years, with 25% vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported a routine equity compensation transaction. On February 15, 2026, he exercised or converted 250 Restricted Stock Units at $0 into 250 shares of Guardant Health common stock.
Following this derivative conversion, Musa directly holds 8,493 shares of common stock and 3,248 Restricted Stock Units. The RSUs were part of an award granted on March 6, 2023 that vests over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years.
Guardant Health director Steve Krognes reported a routine equity compensation event. On January 31, 2026, 154 Restricted Stock Units vested at an exercise price of $0, resulting in the acquisition of 154 shares of common stock. Following this transaction, he directly holds 18,899 shares of common stock and 772 Restricted Stock Units.
The vested RSUs come from an award granted on August 9, 2022, which vested 25% of the shares on June 30, 2023. The remaining 75% vests in substantially equal monthly installments over the three years after June 30, 2023.
Guardant Health Chief People Officer Terilyn J. Monroe reported multiple open-market sales of company stock. On January 21, 2026, she sold 1,703 shares of Guardant Health common stock at a weighted average price of $112.3418 per share, 3,619 shares at a weighted average price of $113.4793 per share, and 3,249 shares at a weighted average price of $115.6978 per share. Each sale was executed in multiple transactions within disclosed price ranges. After these sales, Monroe directly beneficially owned 20,990 shares of Guardant Health common stock.
Guardant Health director Roberto Mignone reported a routine vesting of equity awards. On 01/21/2026, 264 Restricted Stock Units converted into 264 shares of Guardant Health common stock at an exercise price of $0 per share, increasing his directly held common stock to 3,959 shares. The related RSU award, granted on November 8, 2024, vests over four years: 25% of the shares vested on the one-year anniversary of 10/21/2024, and the remaining 75% vests in equal monthly installments over the following three years. After this vesting event, Mignone directly holds 8,712 RSUs in addition to his common shares.
Guardant Health, Inc. (GH) insider Terilyn J. Monroe has filed a Form 144 indicating an intent to sell additional shares of company stock. The filing covers 8,571 shares of common stock to be sold through Charles Schwab & Co., Inc. on or about 01/21/2026 on the NASDAQ, with an aggregate market value of 977902.00. These shares were acquired on 01/15/2026 via a restricted stock lapse as equity compensation from Guardant Health, Inc.
The filing also lists prior sales over the past three months. Monroe sold 55,167 shares of Guardant Health, Inc. on 12/01/2025 for gross proceeds of 5846164.00, and 10,031 shares on 01/07/2026 for gross proceeds of 1124200.00. Guardant Health, Inc. had 126,041,089 shares of common stock outstanding, providing context for the size of these transactions relative to the total share base.
Guardant Health director Manuel Hidalgo Medina reported a routine equity award vesting. On January 17, 2026, 232 Restricted Stock Units converted at an exercise price of $0 into 232 shares of common stock. After this transaction, he beneficially owned 1,261 shares of common stock directly and 6,961 Restricted Stock Units.
The Restricted Stock Units were granted on July 17, 2024 and vest over four years. 25% of the award vested on the one-year anniversary of that grant date, and the remaining 75% vests in equal monthly installments over the following three years.